{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:40:42Z","timestamp":1793032842699,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ijpx.2026.100627","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:00:34Z","timestamp":1785697234000},"page":"100627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A DoE-Dual centrifugation-driven screening platform for liposomal incorporation of poorly soluble APIs: Application to the PROTAC ACBI2"],"prefix":"10.1016","volume":"12","author":[{"given":"Miriam","family":"Jaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"K\u00f6ll-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lembeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"S\u00fcss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2026.100627_bb0005","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijbiomac.2013.11.041","article-title":"Towards better modeling of chitosan nanoparticles production: screening different factors and comparing two experimental designs","volume":"64","author":"Abdel-Hafez","year":"2014","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijpx.2026.100627_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/49.suppl_1.21","article-title":"AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience","volume":"49","author":"Adler-Moore","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpx.2026.100627_bb0015","article-title":"Degraders on demand: engineering smart nanocarriers for PROTAC delivery","author":"Amalraj","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100627_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118352","article-title":"Liposomal formulation of the CDK9 PROTAC THAL-SNS-032 enhances the antitumor activity in breast cancer cell lines","volume":"189","author":"Arenas-Moreira","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijpx.2026.100627_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118892","article-title":"PROTAC delivery systems: innovative approaches for cancer treatment","volume":"194","author":"Arenas-Moreira","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijpx.2026.100627_bb0030","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3390\/cells10081920","article-title":"Perspectives and issues in the assessment of SMARCA4 deficiency in the management of lung cancer patients","volume":"10","author":"Armon","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ijpx.2026.100627_bb0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/acsmedchemlett.0c00556","article-title":"Solution conformations shed light on PROTAC cell permeability","volume":"12","author":"Atilaw","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ijpx.2026.100627_bb0040","series-title":"Design of Experiments for Pharmaceutical Product Development","first-page":"87","article-title":"Mixture designs and their applications in pharmaceutical product development","author":"Beg","year":"2021"},{"key":"10.1016\/j.ijpx.2026.100627_bb0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpx.2026.100627_bb0050","doi-asserted-by":"crossref","DOI":"10.1039\/D5PM00287G","article-title":"Dual centrifugation \u2013 a novel perspective on lipid nanoparticle formulation development","author":"Bender","year":"2026","journal-title":"RSC Pharm."},{"key":"10.1016\/j.ijpx.2026.100627_bb0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0005-2736(01)00290-5","article-title":"Phospholipid-cationic lipid interactions: influences on membrane and vesicle properties","volume":"1512","author":"Campbell","year":"2001","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ijpx.2026.100627_bb0060","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1038\/s41467-022-34562-5","article-title":"Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers","volume":"13","author":"Cantley","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpx.2026.100627_bb0065","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil\u00ae): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijpx.2026.100627_bb0070","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijpx.2026.100627_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124973","article-title":"Liposomes-mediated enhanced antitumor effect of docetaxel with BRD4-PROTAC as synergist for breast cancer chemotherapy\/immunotherapy","volume":"668","author":"Chen","year":"2025","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ijpx.2026.100627_bb0080","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/pharmaceutics12100986","article-title":"Controlled delivery of BET-PROTACs: in vitro evaluation of MZ1-loaded polymeric antibody conjugated nanoparticles in breast cancer","volume":"12","author":"Cimas","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100627_bb0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpx.2026.100627_bb0090","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jtho.2020.01.002","article-title":"Clinicopathologic characteristics of BRG1-deficient NSCLC","volume":"15","author":"Dagogo-Jack","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ijpx.2026.100627_bb0095","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpx.2026.100627_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126112","article-title":"Mapping berberine distribution in liposomes: the role of drug-phospholipid interactions in localization and release","author":"Dhakal","year":"2025","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ijpx.2026.100627_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118675","article-title":"Design, synthesis and pharmacological evaluation of new SMARCA2 degraders bearing a furo[3,2-c]pyridazine scaffold","volume":"308","author":"Diao","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijpx.2026.100627_bb0110","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.1038\/srep07107","article-title":"The role of the helper lipid on the DNA transfection efficiency of lipopolyplex formulations","volume":"4","author":"Du","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpx.2026.100627_bb0115","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/acs.chemrev.3c00608","article-title":"The chemical reactivity of membrane lipids","volume":"124","author":"Duch\u00e9","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ijpx.2026.100627_bb0120","series-title":"ICH Q2(R2) Guideline on Validation of Analytical Procedures","author":"European Medicines Agency (EMA)","year":"2023"},{"key":"10.1016\/j.ijpx.2026.100627_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2021.183794","article-title":"Broad lipid phase transitions in mammalian cell membranes measured by Laurdan fluorescence spectroscopy","volume":"1864","author":"F\u00e4rber","year":"2022","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ijpx.2026.100627_bb0130","series-title":"NDA 219835 Approval","author":"FDA","year":"2026"},{"key":"10.1016\/j.ijpx.2026.100627_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112275","article-title":"Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma","volume":"396","author":"Fu","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ijpx.2026.100627_bb0140","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/pharmaceutics13071005","article-title":"Development of dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma","volume":"13","author":"Fu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100627_bb0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ijpx.2026.100627_bb0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41587-021-01173-2","article-title":"The PROTAC gold rush","volume":"40","author":"Garber","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijpx.2026.100627_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(89)90173-7","article-title":"Hydrolysis of phosphatidylcholine in aqueous liposome dispersions","volume":"50","author":"Grit","year":"1989","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ijpx.2026.100627_bb0160","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41467-023-36238-0","article-title":"A two-faced selectivity solution to target SMARCA2 for cancer therapy","volume":"14","author":"Harling","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpx.2026.100627_bb0165","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1073\/pnas.1316793111","article-title":"Functional epigenetics approach identifies BRM\/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers","volume":"111","author":"Hoffman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijpx.2026.100627_bb0170","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2005.04.003","article-title":"Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes","volume":"105","author":"Ishida","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2026.100627_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2026.100627_bb0180","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1039\/f29767201525","article-title":"Theory of self-assembly of hydrocarbon amphiphiles into micelles and bilayers","volume":"72","author":"Israelachvili","year":"1976","journal-title":"J. Chem. Soc. Faraday Trans."},{"key":"10.1016\/j.ijpx.2026.100627_bb0185","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/1061186X.2023.2185247","article-title":"Albumin-encapsulated HSP90-PROTAC BP3 nanoparticles not only retain protein degradation ability but also enhance the antitumour activity of BP3 in vivo","volume":"31","author":"Jiang","year":"2023","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijpx.2026.100627_bb0190","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.3390\/pharmaceutics13122046","article-title":"Screening for optimal liposome preparation conditions by using dual centrifugation and time-resolved fluorescence measurements","volume":"13","author":"Koehler","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100627_bb0195","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/pharmaceutics15020706","article-title":"Tailoring the lamellarity of liposomes prepared by dual centrifugation","volume":"15","author":"Koehler","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100627_bb0200","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3390\/ph16111519","article-title":"Preparation of nanosized pharmaceutical formulations by dual centrifugation","volume":"16","author":"Koehler","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijpx.2026.100627_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106999","article-title":"Novel thermosensitive small multilamellar lipid nanoparticles with promising release characteristics made by dual centrifugation","volume":"206","author":"Koehler","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100627_bb0210","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1038\/s41467-022-33430-6","article-title":"A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo","volume":"13","author":"Kofink","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpx.2026.100627_bb0215","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/pharmaceutics15082098","article-title":"Development of liposome systems for enhancing the PK properties of bivalent PROTACs","volume":"15","author":"Kou","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100627_bb0220","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1080\/03610920008832606","article-title":"A new model and class of designs for mixture experiments with process variables","volume":"29","author":"Kowalski","year":"2000","journal-title":"Commun. Stat. Theory Methods"},{"key":"10.1016\/j.ijpx.2026.100627_bb0225","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1073\/pnas.88.2.444","article-title":"Complementary molecular shapes and additivity of the packing parameter of lipids","volume":"88","author":"Kumar","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijpx.2026.100627_bb0230","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cite.201800100","article-title":"Statistical Design of Experiments for Screening and Optimization","volume":"91","author":"Lee","year":"2019","journal-title":"Chem. Ing. Tech."},{"key":"10.1016\/j.ijpx.2026.100627_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2026.100627_bb0240","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ijpx.2026.100627_bb0245","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/1087057103256465","article-title":"Technical notes: a simple technique for reducing edge effect in Cell-based assays","volume":"8","author":"Lundholt","year":"2003","journal-title":"SLAS Disc."},{"key":"10.1016\/j.ijpx.2026.100627_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152339","article-title":"Exploring the clinical trials, regulatory insights, and challenges of PROTACs in oncology","volume":"52","author":"M","year":"2025","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ijpx.2026.100627_bb0255","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jconrel.2007.09.010","article-title":"Dual asymmetric centrifugation (DAC)\u2014a new technique for liposome preparation","volume":"125","author":"Massing","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2026.100627_bb0260","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpx.2026.100627_bb0265","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1021\/la980449u","article-title":"Binding of dipyridamole to DPPG and DPPC phospholipid vesicles: steady-state fluorescence and fluorescence anisotropy decay studies","volume":"14","author":"Nassar","year":"1998","journal-title":"Langmuir"},{"key":"10.1016\/j.ijpx.2026.100627_bb0270","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1042\/BCJ20243018","article-title":"Methods to accelerate PROTAC drug discovery","volume":"482","author":"Osman","year":"2025","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijpx.2026.100627_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202501384","article-title":"Remodeling the physicochemical and pharmacokinetic properties of PROTAC via lipid nanodisks for cancer therapy","volume":"12","author":"Pan","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijpx.2026.100627_bb0280","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10529-005-5803-x","article-title":"A Pitfall of the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay due to evaporation in wells on the edge of a 96 well plate","volume":"27","author":"Patel","year":"2005","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ijpx.2026.100627_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126358","article-title":"Microfluidic-assisted preparation of ARV 825 and Osimertinib loaded liposomal formulation as a potential system for colorectal cancer therapy","volume":"686","author":"Patel","year":"2025","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ijpx.2026.100627_bb0290","doi-asserted-by":"crossref","first-page":"8038","DOI":"10.1038\/s41467-023-43892-x","article-title":"Nonuniversal impact of cholesterol on membranes mobility, curvature sensing and elasticity","volume":"14","author":"P\u00f6hnl","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpx.2026.100627_bib371","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science."},{"key":"10.1016\/j.ijpx.2026.100627_bb0295","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2217\/nnm-2020-0156","article-title":"Nanoformulation of PROteolysis TArgeting Chimera targeting \u2018undruggable\u2019 c-Myc for the treatment of pancreatic cancer","volume":"15","author":"Saraswat","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ijpx.2026.100627_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e08702","article-title":"Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy","volume":"8","author":"Saraswat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ijpx.2026.100627_bb0305","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.xphs.2021.03.017","article-title":"A review of formulations of commercially available antibodies","volume":"110","author":"Strickley","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100627_bb0310","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.ijpx.2026.100627_bb0315","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1081\/LPR-120004790","article-title":"Rofe of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies","volume":"12","author":"Szebeni","year":"2002","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ijpx.2026.100627_bb0320","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1158\/0008-5472.CAN-14-3798","article-title":"The SMARCA2\/4 ATPase domain surpasses the bromodomain as a drug target in SWI\/SNF-Mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies","volume":"75","author":"Vangamudi","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpx.2026.100627_bb0325","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1038\/ncomms5916","article-title":"A sub-nanometre view of how membrane curvature and composition modulate lipid packing and protein recruitment","volume":"5","author":"Vanni","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpx.2026.100627_bb0330","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s11095-022-03184-3","article-title":"Susceptibility of lung carcinoma cells to nanostructured lipid carrier of ARV-825, a BRD4 degrading proteolysis targeting chimera","volume":"39","author":"Vartak","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100627_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101512","article-title":"Nanoparticle-based medicines in clinical cancer therapy","volume":"45","author":"Wang","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.ijpx.2026.100627_bb0340","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2219869","article-title":"Negatively charged phospholipids doped liposome delivery system for mRNA with high transfection efficiency and low cytotoxicity","volume":"30","author":"Wang","year":"2023","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijpx.2026.100627_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22241","article-title":"Targeted degradation of KRAS protein in non-small cell lung cancer: therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles","volume":"85","author":"Wang","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ijpx.2026.100627_bb0350","article-title":"Ginsenoside Rh2- functionalized liposomes enhanced BRD4-PROTAC delivery and antitumor efficacy via improved tumor targeting and ECM remodeling","volume":"36","author":"Wen","year":"2026","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.ijpx.2026.100627_bb0355","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/MCB.01372-13","article-title":"Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation","volume":"34","author":"Wilson","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ijpx.2026.100627_bb0360","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1021\/acs.langmuir.9b00572","article-title":"Influence of cholesterol and bilayer curvature on the interaction of PPO\u2013PEO block copolymers with liposomes","volume":"35","author":"Zhang","year":"2019","journal-title":"Langmuir"},{"key":"10.1016\/j.ijpx.2026.100627_bb0365","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jcis.2024.08.185","article-title":"Co-delivery of PROTAC and siRNA via novel liposomes for the treatment of malignant tumors","volume":"678","author":"Zhang","year":"2025","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ijpx.2026.100627_bb0370","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/jps.2600840915","article-title":"Chemical hydrolysis of phospholipids","volume":"84","author":"Zuidam","year":"1995","journal-title":"J. Pharm. Sci."}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726001477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726001477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:10:00Z","timestamp":1793031000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156726001477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":75,"alternative-id":["S2590156726001477"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100627","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A DoE-Dual centrifugation-driven screening platform for liposomal incorporation of poorly soluble APIs: Application to the PROTAC ACBI2","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100627"}}